Piceatannol, a Derivative of Resveratrol, Moderately Slows I(Na) Inactivation and Exerts Antiarrhythmic Action in Ischaemia-reperfused Rat Hearts

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2009 Apr 18

PMID 19371352

Citations 13

Authors

Wen-Pin Chen

Li-Man Hung

Chia-Hsiang Hsueh

Ling-Ping Lai

Ming-Jai Su

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Piceatannol is more potent than resveratrol in free radical scavenging in association with antiarrhythmic and cardioprotective activities in ischaemic-reperfused rat hearts. The present study aimed to investigate the antiarrhythmic efficacy and the underlying ionic mechanisms of piceatannol in rat hearts.

Experimental Approach: Action potentials and membrane currents were recorded by the whole-cell patch clamp techniques. Fluo-3 fluorimetry was used to measure cellular Ca2+ transients. Antiarrhythmic activity was examined from isolated Langendorff-perfused rat hearts.

Key Results: In rat ventricular cells, piceatannol (3-30 micromol.L(-1)) prolonged the action potential durations (APDs) and decreased the maximal rate of upstroke (V(max)) without altering Ca2+ transients. Piceatannol decreased peak I(Na) and slowed I(Na) inactivation, rather than induced a persistent non-inactivating current, which could be reverted by lidocaine. Resveratrol (100 micromol.L(-1)) decreased peak I(Na) without slowing I(Na) inactivation. The inhibition of peak I(Na) or V(max) was associated with a negative shift of the voltage-dependent steady-state I(Na) inactivation curve without altering the activation threshold. At the concentrations more than 30 micromol.L(-1), piceatannol could inhibit I(Ca,L), I(to), I(Kr), Ca2+ transients and Na+-Ca2+ exchange except I(K1). Piceatannol (1-10 micromol.L(-1)) exerted antiarrhythmic activity in isolated rat hearts subjected to ischaemia-reperfusion injury.

Conclusions And Implications: The additional hydroxyl group on resveratrol makes piceatannol possessing more potent in I(Na) inhibition and uniquely slowing I(Na) inactivation, which may contribute to its antiarrhythmic actions at low concentrations less than 10 micromol.L(-1).

Citing Articles

Therapeutic and Nutraceutical Effects of Polyphenolics from Natural Sources.

Sahiner M, Yilmaz A, Gungor B, Ayoubi Y, Sahiner N Molecules. 2022; 27(19).

PMID: 36234762 PMC: 9572829. DOI: 10.3390/molecules27196225.

Resveratrol and Curcumin for Chagas Disease Treatment-A Systematic Review.

Lima Imperador C, Scarim C, Bosquesi P, Lopes J, Neto A, Giarolla J Pharmaceuticals (Basel). 2022; 15(5).

PMID: 35631435 PMC: 9143057. DOI: 10.3390/ph15050609.

Synergistic FRET assays for drug discovery targeting RyR2 channels.

Rebbeck R, Ginsburg K, Ko C, Fasoli A, Rusch K, Cai G J Mol Cell Cardiol. 2022; 168:13-23.

PMID: 35405106 PMC: 10088286. DOI: 10.1016/j.yjmcc.2022.04.002.

Piceatannol Affects Gastric Ulcers Induced by Indomethacin: Association of Antioxidant, Anti-Inflammatory, and Angiogenesis Mechanisms in Rats.

Shaik R, Eid B Life (Basel). 2022; 12(3).

PMID: 35330107 PMC: 8953771. DOI: 10.3390/life12030356.

Piceatannol suppresses inflammation and promotes apoptosis in rheumatoid arthritis‑fibroblast‑like synoviocytes by inhibiting the NF‑κB and MAPK signaling pathways.

Gao X, Kang X, Lu H, Xue E, Chen R, Pan J Mol Med Rep. 2022; 25(5).

PMID: 35322865 PMC: 8972314. DOI: 10.3892/mmr.2022.12696.

References

Aggarwal B, Sethi G, Ahn K, Sandur S, Pandey M, Kunnumakkara A . Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci. 2007; 1091:151-69. DOI: 10.1196/annals.1378.063. View

Das D, Sato M, Ray P, Maulik G, Engelman R, Bertelli A . Cardioprotection of red wine: role of polyphenolic antioxidants. Drugs Exp Clin Res. 1999; 25(2-3):115-20. View

Sada K, Takano T, Yanagi S, Yamamura H . Structure and function of Syk protein-tyrosine kinase. J Biochem. 2001; 130(2):177-86. DOI: 10.1093/oxfordjournals.jbchem.a002970. View

Marier J, Vachon P, Gritsas A, Zhang J, Moreau J, Ducharme M . Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther. 2002; 302(1):369-73. DOI: 10.1124/jpet.102.033340. View

Potter G, Patterson L, Wanogho E, Perry P, Butler P, Ijaz T . The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer. 2002; 86(5):774-8. PMC: 2375304. DOI: 10.1038/sj.bjc.6600197. View

Yuill K, Convery M, Dooley P, Doggrell S, Hancox J . Effects of BDF 9198 on action potentials and ionic currents from guinea-pig isolated ventricular myocytes. Br J Pharmacol. 2000; 130(8):1753-66. PMC: 1572251. DOI: 10.1038/sj.bjp.0703476. View

Manning A, Coltart D, Hearse D . Ischemia and reperfusion-induced arrhythmias in the rat. Effects of xanthine oxidase inhibition with allopurinol. Circ Res. 1984; 55(4):545-8. DOI: 10.1161/01.res.55.4.545. View

Tikhonov D, Zhorov B . Sodium channel activators: model of binding inside the pore and a possible mechanism of action. FEBS Lett. 2005; 579(20):4207-12. DOI: 10.1016/j.febslet.2005.07.017. View

Jones E, Roti Roti E, Wang J, Delfosse S, Robertson G . Cardiac IKr channels minimally comprise hERG 1a and 1b subunits. J Biol Chem. 2004; 279(43):44690-4. DOI: 10.1074/jbc.M408344200. View

10.

Abtahian F, Guerriero A, Sebzda E, Lu M, Zhou R, Mocsai A . Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science. 2003; 299(5604):247-51. PMC: 2982679. DOI: 10.1126/science.1079477. View

11.

Roupe K, Teng X, Fu X, Meadows G, Davies N . Determination of piceatannol in rat serum and liver microsomes: pharmacokinetics and phase I and II biotransformation. Biomed Chromatogr. 2004; 18(8):486-91. DOI: 10.1002/bmc.342. View

12.

Roupe K, Yanez J, Teng X, Davies N . Pharmacokinetics of selected stilbenes: rhapontigenin, piceatannol and pinosylvin in rats. J Pharm Pharmacol. 2006; 58(11):1443-50. DOI: 10.1211/jpp.58.11.0004. View

13.

Boocock D, Faust G, Patel K, Schinas A, Brown V, Ducharme M . Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007; 16(6):1246-52. DOI: 10.1158/1055-9965.EPI-07-0022. View

14.

Waffo Teguo P , Fauconneau , Deffieux , HUGUET , Vercauteren , Merillon . Isolation, identification, and antioxidant activity of three stilbene glucosides newly extracted from vitis vinifera cell cultures . J Nat Prod. 1998; 61(5):655-7. DOI: 10.1021/np9704819. View

15.

Renaud S, de Lorgeril M . Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 1992; 339(8808):1523-6. DOI: 10.1016/0140-6736(92)91277-f. View

16.

Chen W, Su M, Hung L . In vitro electrophysiological mechanisms for antiarrhythmic efficacy of resveratrol, a red wine antioxidant. Eur J Pharmacol. 2006; 554(2-3):196-204. DOI: 10.1016/j.ejphar.2006.10.016. View

17.

Hung L, Chen J, Lee R, Liang H, Su M . Beneficial effects of astringinin, a resveratrol analogue, on the ischemia and reperfusion damage in rat heart. Free Radic Biol Med. 2001; 30(8):877-83. DOI: 10.1016/s0891-5849(01)00474-9. View

18.

Hung L, Chen J, Huang S, Lee R, Su M . Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res. 2000; 47(3):549-55. DOI: 10.1016/s0008-6363(00)00102-4. View

19.

Ferrigni N, McLaughlin J, Powell R, Smith Jr C . Use of potato disc and brine shrimp bioassays to detect activity and isolate piceatannol as the antileukemic principle from the seeds of Euphorbia lagascae. J Nat Prod. 1984; 47(2):347-52. DOI: 10.1021/np50032a019. View

20.

Cooper L, Longnecker R . Inhibition of host kinase activity altered by the LMP2A signalosome-a therapeutic target for Epstein-Barr virus latency and associated disease. Antiviral Res. 2002; 56(3):219-31. DOI: 10.1016/s0166-3542(02)00110-9. View